MRNA +104% on acquisition of Turing Parma’s intranasal ketamine: http://finance.yahoo.com/news/marina-biotech-acquire-stage-program-130000489.html For people who remember NSTK (MRNA’s former incarnation) and its CEO, Steven Quay, there’s irony in today’s deal.